[Kinetic patterns of cytokine expressions in H-2 haploidentical nonmyeloablative bone marrow transplantation in mice].
In order to explore what role relative cytokines play in acute GVHD (aGVHD) of mice transplanted with H-2 haploidentical nonmyeloablative bone marrow, a murine model was established by using C57BL/6J mouse as donor and (C57BL/6J x BALB/C) F1 mouse as the recipient. The recipient mice were given CsA and mycophenolate mofetile (MMF) for prophylaxis of aGVHD. The expression levels of IL-2, INFgamma, IL-4 and IL-10 in the spleen were detected by semi-quantitative RT-PCR at different time points after transplantation. The results showed that the expression levels of these cytokines increased slightly in the group only received nonmyeloablative conditioning. The expression levels of IL-2 and INF-gamma elevated significantly after transplantation in group 2 (without aGVHD prophylaxis), peaked at day 21 and day 14 respectively, then dropped rapidly, returned to the basal levels at day 35. The study on kinetic pattern of expression of IL-2 and INF-gamma in group 3 (with aGVHD prophylaxis) gave a similar result to group 2, but the peak value of cytokine expression in group 3 was much lower than that in group 2. The expression of IL-4 in Group 2 and group 3 all peaked at day 14, but the peak value in group 3 was higher than that in group 2, and decreased slowly in group 3. The expression of IL-10 increased gradually after transplantation, peaked at day 14, decreased after day 21, elevated again until day 35. It is concluded that the expression levels of these cytokines in the spleen all increase after H-2 haploidentical nonmyeloablative bone marrow transplantation. CsA and MMF can reduce the incidence and severity of aGVHD by down-regulating the expression levels of IL-2 and INF-gamma.
Li
Xin
X
Department of Hematology, The Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100039, China.
Sun
Wan-Jun
WJ
Yuan
Ye
Y
Mao
Ning
N
Ai
Hui-Sheng
HS
D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000379:methods*; D016572:Cyclosporine / Q000008:administration & dosage; D016207:Cytokines / Q000235:genetics*; D015870:Gene Expression / Q000187:drug effects; D006086:Graft vs Host Disease / Q000517:prevention & control; D006183:H-2 Antigens / Q000235:genetics*; D007371:Interferon-gamma / Q000235:genetics; D007376:Interleukin-2 / Q000235:genetics; D007700:Kinetics; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D020133:Reverse Transcriptase Polymerase Chain Reaction
D016207:Cytokines; D006183:H-2 Antigens; D007376:Interleukin-2; D007371:Interferon-gamma; D016572:Cyclosporine; D009173:Mycophenolic Acid